期刊文献+

人脐血树突状细胞抗神经胶质瘤的体外免疫效应研究

Antiglioma effect of dendritic cells derived from human cord blood in vitro
下载PDF
导出
摘要 目的 研究肿瘤抗原致敏的树突状细胞 (DC)对神经胶质瘤细胞的免疫杀伤效应。方法 应用免疫磁珠分选脐血 CD34细胞 ,经 SCF+FL3+GM- CSF+IL- 4 +TNF- α的联合诱导培养 DC,采用相差显微镜观察树突状细胞的形态 ;流式细胞仪作 DC的表面标志检测 ;MTT比色法测定同种异型的混合淋巴细胞反应能力和诱导CTL 毒性的检测。结果  (1)脐血 CD34细胞在体外经细胞因子联合刺激后呈典型的 DC形态 ;(2 )流式检测 CD4 0、CD80和 CD86等成熟 DC特异性表面标志呈高表达 ,分别与诱导前比较 ,差异均有显著性 ;(3) MTT法测得脐血来源的 DC较外周血 DC刺激同种异体 T淋巴细胞增殖能力弱 ;经肿瘤抗原负载的 DC体外诱导出较强 CTL 毒性。结论 脐血 CD34细胞经体外扩增诱导的 DC具有典型的 CTL 毒性 ,为临床应用脐血来源 Objective To investigate the antiglioma e ffect of the CD34+ dendritic cells derived from human cord blood in vitro. Methods CD34+ mononuclear cells were isolated from neonatal cor d blood by ficoll centrifugation and magnetic se-paration technique, then cultu red with cytokines (SCF,FL-3,GM-CSF,IL-4,TNF-α). After two weeks of culture , the cells were checked by FACS. The allo-MLR and CTL were detected by MTT me thod.Results (1) CD34+ mononuclear cells from cord blood exh ibited distinctive morphological features of dendritic cell after culture. (2) F low cytometry demonstrated CD40, CD80, CD86 expressed on the mature DCs. (3)Allo -mixed lymphocyte reaction showed that DCs from cord blood stimulated by tumor antigens (SHG-44) induced stronger CTL reaction. Conclusion C D34 dendritic cells from cord blood are capable of inducing antiglioma respons e in vitro.
出处 《实用肿瘤杂志》 CAS 北大核心 2004年第6期487-490,共4页 Journal of Practical Oncology
基金 浙江省医药卫生重点科技项目 (No 2 0 0 1-2 D0 0 0 8)
关键词 胎血 树突细胞 神经胶质瘤 抗原 肿瘤 免疫疗法 fetal blood dendritic cells glioma an tigens,neoplasm immunotherapy
  • 相关文献

参考文献11

  • 1Dix AR, Brooks WH, Morford LA. Immune defects observed patients with primary malignant brain tumors [J].J Neuroimnunol,1999,100(1-2):216-232.
  • 2Yamanaka R,Yajima N,Abe T,et al.Dendritic cell-based glioma immunotherapy [J]. Int J Oncol,2003,23(1):5-15.
  • 3Parney LF, Hao C, Petruk KC. Glioma immunology and immunotherapy [J].Neurosurgery,2000,46(4):778-786.
  • 4Sankhla SK,Nadkarni JS,Bhagwati SN.Adoptive immunotherapy using lymphokine-activated (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors [J].J Neuroncol,1995,27(2):133-140.
  • 5Derek N,Hart J.Dendritic cell: unique leukocyte population which control the primary immune response [J].Blood,1997,90(9):3245-3287.
  • 6朱学军,曹雪涛,于益芝,陈国友,万涛,马施华,唐华,章卫平.人外周血树突状细胞的体外扩增及鉴定[J].中国肿瘤生物治疗杂志,1997,4(4):302-306. 被引量:91
  • 7沈关心,周钕麟.现代免疫学实验技术[M].第二版,武汉:湖北科学技术出版社,2001.108-115.
  • 8Svetlana N,Bykovskala Y,Galina V,et al.Differentiation of immunostimulatory stem-cell and monocyte-derived dendritic cells involves maturation of intracellular compartments responsible for antigen presentation and secretion [J].Stem Cells,2002,20(2):380-393.
  • 9Zitvogel L,Mayordomo JI,Tjandrawan T,et al.Therapy of murine tumor with tumor peptide-pulsed dendritic cells: dependence on T cells,B7 costimulation and T helper cell-associated cytokines [J].J Exp Med,1996,183(1):87-97.
  • 10Schreurs MW,Eggert AA,Punt CJ,et al.Dendritic cell-based vaccines:from mouse models to clinical cancer immunotherapy [J].Crit Rev Oncog,2000,11(1):1-17.

共引文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部